Divergent responses of human intestinal organoid monolayers using commercial in vitro cytotoxicity assays
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0304526 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Miranda A Lewis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, Texas, United States of America. Hauptthemen laut MEDLINE: Organoids, L-Lactate Dehydrogenase. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
In vitro models, such as primary cells and continuous cell lines routinely used for evaluating drug candidates, have limitations in their translational relevance to human diseases. Organotypic cultures are increasingly being used to assess therapeutics for various cancers and infectious diseases. Monitoring drug cytotoxicity in cell cultures is crucial in drug development, and several commercially available kits for cytotoxicity assessment offer distinct advantages and limitations. Given the complexity of organoid cultures, including donor-driven variability, we investigated drug-treated, tissue stem cell-derived human intestinal organoid responses with commonly used cell cytotoxicity assay kits. Using seven different compounds, we compared the cytotoxicity assay performance of two different leaky membrane-based and two metabolism-based assays. Significant variability was seen in reported viability outcomes across assays and organoid lines. High baseline activity of lactate dehydrogenase (LDH) in four human intestinal organoid lines required modification of the standard LDH assay protocol. Additionally, the LDH assay reported unique resilience to damage in a genetically-modified line contrasting results compared to other assays. This study highlights factors that can impact the measurement of cell cytotoxicity in intestinal organoid models, which are emerging as valuable new tools for research and pre-clinical drug testing and suggest the need for using multiple assay types to ensure reliable cytotoxicity assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, Texas, United States of America.
- Department of Medicine, Baylor College of Medicine, Houston, Texas, United States of America.
ORCID-Profile: Sasirekha Ramani
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
- NCI NIH HHS
- NIDDK NIH HHS
- NCRR NIH HHS
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- National Institute of General Medical Sciences
Zitieren
APA
Lewis, M. A., Patil, K., Ettayebi, K., Estes, M. K., Atmar, R. L., & Ramani, S. (2024). Divergent responses of human intestinal organoid monolayers using commercial in vitro cytotoxicity assays. PLOS ONE. https://doi.org/10.1371/journal.pone.0304526
Vancouver
Lewis MA, Patil K, Ettayebi K, Estes MK, Atmar RL, Ramani S. Divergent responses of human intestinal organoid monolayers using commercial in vitro cytotoxicity assays. PLOS ONE. 2024. doi:10.1371/journal.pone.0304526
BibTeX
@article{Lewis2024,
author = {Lewis, Miranda A and Patil, Ketki and Ettayebi, Khalil and Estes, Mary K and Atmar, Robert L and Ramani, Sasirekha},
title = {Divergent responses of human intestinal organoid monolayers using commercial in vitro cytotoxicity assays},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0304526}
}
EUVIMED